Why this matters: A "normal" codeine dose is safe for most but dangerous for ultra-rapid metabolizers—they produce too much morphine too fast (infants have died from breastfeeding mothers with this genotype).
The study of how genetic variations influence individual drug responses (efficacy and toxicity), combining pharmacology and genomics to enable personalized medicine.
What are the four ADME processes and how do genetics affect them?
What does SLCO1B1 (OATP1B1) actually do, and why does its variant raise statin myopathy risk?
It is a HEPATIC UPTAKE transporter that moves statins from blood INTO liver cells (not a gut absorption transporter). Loss-of-function variant (c.521T>C) → less liver uptake → higher blood/muscle statin exposure → increased myopathy risk (odds ratio ~4.5 for CC vs TT).
How do CYP2D6 ultra-rapid metabolizers respond to codeine?
They rapidly convert codeine to morphine, producing HIGHER, faster morphine levels — often enhanced analgesia but with serious toxicity risk (respiratory depression). Only the codeine→morphine conversion is accelerated; morphine's own clearance is unchanged.
How do CYP2D6 POOR metabolizers respond to codeine?
They cannot convert codeine to morphine, so they get little or no analgesia even at normal doses.
Derive how VKORC1 variant affects warfarin dosing
Dose_variant = Dose_normal × (IC50_variant / IC50_normal). If the variant enzyme is more sensitive (IC50 halved), the dose is halved to achieve the same inhibition. Add CYP2C9 poor metabolizer → slower clearance → reduce further.
What is HLA-B*5701 and why test for it?
An MHC class I allele that presents abacavir-peptide complexes to T cells, triggering hypersensitivity (fever, rash, organ damage). Testing before abacavir prevents life-threatening reactions (~8% → <1%).
Explain why tramadol fails in CYP2D6 poor metabolizers
Tramadol is an inactive prodrug needing CYP2D6 to form O-desmethyltramadol (much more potent). Poor metabolizers lack this conversion → no analgesia; raising the dose risks seizures from the parent compound.
Odds ratio vs absolute risk in pharmacogenomics?
An odds ratio (e.g., ~4.5 for SLCO1B1 CC) compares odds, not absolute event rates. With a rare baseline (myopathy), even a sizeable OR keeps absolute risk low — never treat an OR as a literal fold-increase in personal risk.
Recall Explain to a 12-Year-Old
Imagine medicine is like a key that needs to fit your body's lock. But everyone's lock is slightly different because of their DNA!
Some people have "fast locks" that turn certain medicines into their active form super quickly. For codeine, "fast" people make lots of the strong stuff (morphine) really fast — which can actually be too much and dangerous. "Slow" people can't turn the key at all, so codeine does nothing for their pain.
Other medicines, like statins for cholesterol, need to be pulled into the liver by a tiny door called SLCO1B1. If your door is small (a gene variant), the medicine stays floating in your blood and can hurt your muscles. So scientists read your DNA first to pick the right medicine and the right dose. It's like a cheat code for your own body!
3.4.2-Liver-metabolism – Hepatic phase I/II reactions, CYP450 and OATP1B1 localization
4.5.1-Immune-recognition – HLA system and hypersensitivity mechanisms
2.1.6-Membrane-transporters – ABC (P-gp) and SLC (OATP1B1) families in drug handling
Clinical note: As of 2026, FDA labels include pharmacogenomic information for 400+ drugs. CPIC guidelines provide dosing recommendations. Direct-to-consumer tests exist but require physician interpretation.
Socho tumne ek painkiller apne saare classmates ko di, aur kisi ko 20 minute mein aaram mila, kisi ko 2 ghante lag gaye, aur kisi ko toh ulta side effects aa gaye. Aisa kyun? Kyunki har insaan ke DNA mein chhoti-chhoti genetic variations hoti hain jo decide karti hain ki drug body mein kaise absorb, metabolize aur clear hoga. Yahi core idea hai pharmacogenomics ka — yeh study karta hai ki tumhara genetic makeup dawai ke response ko kaise affect karta hai. Koi "fast metabolizer" hota hai jo drug ko itni jaldi clear kar deta hai ki asar hi nahi hota, aur koi "slow metabolizer" jiske body mein drug jama hokar toxic level tak pahunch jata hai.
Ab isko samajhne ke liye teen pillars yaad rakho. Pehla hai pharmacokinetics — yaani "body drug ke saath kya karti hai" — jismein ADME framework aata hai (Absorption, Distribution, Metabolism, Excretion). Yahan CYP450 enzymes bahut important hain, jaise CYP2D6 jo codeine ko morphine mein badalta hai; agar tum ultra-rapid metabolizer ho toh normal dose bhi khatarnak ban sakta hai. Dusra pillar hai pharmacodynamics — "drug body ke saath kya karta hai" — jaise warfarin ka example jahan VKORC1 gene ke variant ki wajah se kam dose hi kaafi hota hai. Aur teesra hai immune-mediated reactions, jaise HLA-B*5701 allele wale logon ko abacavir se jaanleva reaction ho sakta hai.
Yeh matter isliye karta hai kyunki "one size fits all" wali dawai ki soch galat hai. Agar doctor pehle hi tumhara genotype check kar le, toh woh sahi drug aur sahi dose de sakta hai — na overdose ka bleeding ka risk, na underdose se treatment fail. Real example dekho: HLA-B*5701 test karne se abacavir reactions 8% se ghatkar 1% se bhi kam ho gaye. Toh pharmacogenomics ka asli maksad hai personalized medicine — har patient ko uske DNA ke hisaab se safe aur effective treatment dena, taki dawai kaam bhi kare aur nuksan bhi na pahunchaye.